Due to gene mutation (i.e., RAS, TP53), the anti-viral infection ability of cancer cells is weakened, which gives the oncolytic viruses a chance (Chiocca 2002) to infect the cancer cells. This evidence concerns the gene TP53 and viral infectious disease.